Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPMP (Ebastel) for protection against provocation-related cognitive impairment in physical urticaria
2005-002582-37Phase 3Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of eribulin in physical urticaria, Cold urticaria (CU) and Dermatographia (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Primary efficacy endpoint and Ability to cope with pressure after provocation. Started Oct 2005; status: completed.
02
Drugs
eribulin
03
Conditions
physical urticariaCold urticaria (CU)Dermatographia
Beyond the preview
Go deeper on 2005-002582-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002582-37.